Treatment of Acromegalic Osteopathy in Real-life Clinical Practice: The BAAC (Bone Active Drugs in Acromegaly) Study

G. Mazziotti; C. Battista; F. Maffezzoni; S. Chiloiro; E. Ferrante; N. Prencipe; L. Grasso; F. Gatto; R. Olivetti; M. Arosio; M. Barale; A. Bianchi; M. Cellini; I. Chiodini; L. De Marinis; G. Del Sindaco; C. Di Somma; A. Ferlin; E. Ghigo; A. Giampietro; S. Grottoli; E. Lavezzi; G. Mantovani; E. Morenghi; R. Pivonello; T. Porcelli; M. Procopio; F. Pugliese; A. Scillitani; A.G. Lania

doi:10.1210/clinem/dgaa363

Treatment of Acromegalic Osteopathy in Real-life Clinical Practice: The BAAC (Bone Active Drugs in Acromegaly) Study

G. Mazziotti, C. Battista, F. Maffezzoni, S. Chiloiro, E. Ferrante, N. Prencipe, L. Grasso, F. Gatto, R. Olivetti, M. Arosio, M. Barale, A. Bianchi, M. Cellini, I. Chiodini, L. De Marinis, G. Del Sindaco, C. Di Somma, A. Ferlin, E. Ghigo, A. GiampietroS. Grottoli, E. Lavezzi, G. Mantovani, E. Morenghi, R. Pivonello, T. Porcelli, M. Procopio, F. Pugliese, A. Scillitani, A.G. Lania

Research output: Contribution to journal › Article › peer-review

Abstract

BACKGROUND: Vertebral fractures (VFs) are a frequent complication of acromegaly, but no studies have been so far published on effectiveness of antiosteoporotic drugs in this clinical setting. OBJECTIVE: To evaluate whether in real-life clinical practice bone active drugs may reduce the risk of VFs in patients with active or controlled acromegaly. STUDY DESIGN: Retrospective, longitudinal study including 9 tertiary care endocrine units. PATIENTS AND METHODS: Two hundred and forty-eight patients with acromegaly (104 males; mean age 56.00 ± 13.60 years) were evaluated for prevalent and incident VFs by quantitative morphometric approach. Bone active agents were used in 52 patients (20.97%) and the median period of follow-up was 48 months (range 12-132). RESULTS: During the follow-up, 65 patients (26.21%) developed incident VFs in relationship with pre-existing VFs (odds ratio [OR] 3.75; P

Original language	English
Journal	J. Clin. Endocrinol. Metab.
Volume	105
Issue number	9
DOIs	https://doi.org/10.1210/clinem/dgaa363
Publication status	Published - 2020

Keywords

NEUROSCIENZE
STUDIO CLINICO
RIS

Access to Document

10.1210/clinem/dgaa363

https://www.scopus.com/inward/record.uri?eid=2-s2.0-85088495183&doi=10.1210%2fclinem%2fdgaa363&partnerID=40&md5=10bc7e0d95a2df44eeafd2f476e18511

Fingerprint Dive into the research topics of 'Treatment of Acromegalic Osteopathy in Real-life Clinical Practice: The BAAC (Bone Active Drugs in Acromegaly) Study'. Together they form a unique fingerprint.

Cite this

Mazziotti, G., Battista, C., Maffezzoni, F., Chiloiro, S., Ferrante, E., Prencipe, N., Grasso, L., Gatto, F., Olivetti, R., Arosio, M., Barale, M., Bianchi, A., Cellini, M., Chiodini, I., De Marinis, L., Del Sindaco, G., Di Somma, C., Ferlin, A., Ghigo, E., ... Lania, A. G. (2020). Treatment of Acromegalic Osteopathy in Real-life Clinical Practice: The BAAC (Bone Active Drugs in Acromegaly) Study. J. Clin. Endocrinol. Metab., 105(9). https://doi.org/10.1210/clinem/dgaa363

Treatment of Acromegalic Osteopathy in Real-life Clinical Practice: The BAAC (Bone Active Drugs in Acromegaly) Study. / Mazziotti, G.; Battista, C.; Maffezzoni, F.; Chiloiro, S.; Ferrante, E.; Prencipe, N.; Grasso, L.; Gatto, F.; Olivetti, R.; Arosio, M.; Barale, M.; Bianchi, A.; Cellini, M.; Chiodini, I.; De Marinis, L.; Del Sindaco, G.; Di Somma, C.; Ferlin, A.; Ghigo, E.; Giampietro, A.; Grottoli, S.; Lavezzi, E.; Mantovani, G.; Morenghi, E.; Pivonello, R.; Porcelli, T.; Procopio, M.; Pugliese, F.; Scillitani, A.; Lania, A.G.

In: J. Clin. Endocrinol. Metab., Vol. 105, No. 9, 2020.

Research output: Contribution to journal › Article › peer-review

Mazziotti, G, Battista, C, Maffezzoni, F, Chiloiro, S, Ferrante, E, Prencipe, N, Grasso, L, Gatto, F, Olivetti, R, Arosio, M, Barale, M, Bianchi, A, Cellini, M, Chiodini, I, De Marinis, L, Del Sindaco, G, Di Somma, C, Ferlin, A, Ghigo, E, Giampietro, A, Grottoli, S, Lavezzi, E, Mantovani, G , Morenghi, E, Pivonello, R, Porcelli, T, Procopio, M, Pugliese, F, Scillitani, A & Lania, AG 2020, 'Treatment of Acromegalic Osteopathy in Real-life Clinical Practice: The BAAC (Bone Active Drugs in Acromegaly) Study', J. Clin. Endocrinol. Metab., vol. 105, no. 9. https://doi.org/10.1210/clinem/dgaa363

Mazziotti, G. ; Battista, C. ; Maffezzoni, F. ; Chiloiro, S. ; Ferrante, E. ; Prencipe, N. ; Grasso, L. ; Gatto, F. ; Olivetti, R. ; Arosio, M. ; Barale, M. ; Bianchi, A. ; Cellini, M. ; Chiodini, I. ; De Marinis, L. ; Del Sindaco, G. ; Di Somma, C. ; Ferlin, A. ; Ghigo, E. ; Giampietro, A. ; Grottoli, S. ; Lavezzi, E. ; Mantovani, G. ; Morenghi, E. ; Pivonello, R. ; Porcelli, T. ; Procopio, M. ; Pugliese, F. ; Scillitani, A. ; Lania, A.G. / Treatment of Acromegalic Osteopathy in Real-life Clinical Practice: The BAAC (Bone Active Drugs in Acromegaly) Study. In: J. Clin. Endocrinol. Metab. 2020 ; Vol. 105, No. 9.

@article{b1ff5c9615b04027a8a28eeb2cef9bd1,

title = "Treatment of Acromegalic Osteopathy in Real-life Clinical Practice: The BAAC (Bone Active Drugs in Acromegaly) Study",

abstract = "BACKGROUND: Vertebral fractures (VFs) are a frequent complication of acromegaly, but no studies have been so far published on effectiveness of antiosteoporotic drugs in this clinical setting. OBJECTIVE: To evaluate whether in real-life clinical practice bone active drugs may reduce the risk of VFs in patients with active or controlled acromegaly. STUDY DESIGN: Retrospective, longitudinal study including 9 tertiary care endocrine units. PATIENTS AND METHODS: Two hundred and forty-eight patients with acromegaly (104 males; mean age 56.00 ± 13.60 years) were evaluated for prevalent and incident VFs by quantitative morphometric approach. Bone active agents were used in 52 patients (20.97%) and the median period of follow-up was 48 months (range 12-132). RESULTS: During the follow-up, 65 patients (26.21%) developed incident VFs in relationship with pre-existing VFs (odds ratio [OR] 3.75; P ",

keywords = "NEUROSCIENZE, STUDIO CLINICO, RIS",

author = "G. Mazziotti and C. Battista and F. Maffezzoni and S. Chiloiro and E. Ferrante and N. Prencipe and L. Grasso and F. Gatto and R. Olivetti and M. Arosio and M. Barale and A. Bianchi and M. Cellini and I. Chiodini and {De Marinis}, L. and {Del Sindaco}, G. and {Di Somma}, C. and A. Ferlin and E. Ghigo and A. Giampietro and S. Grottoli and E. Lavezzi and G. Mantovani and E. Morenghi and R. Pivonello and T. Porcelli and M. Procopio and F. Pugliese and A. Scillitani and A.G. Lania",

year = "2020",

doi = "10.1210/clinem/dgaa363",

language = "English",

volume = "105",

journal = "J. Clin. Endocrinol. Metab.",

issn = "1945-7197",

number = "9",

}

TY - JOUR

T1 - Treatment of Acromegalic Osteopathy in Real-life Clinical Practice: The BAAC (Bone Active Drugs in Acromegaly) Study

AU - Mazziotti, G.

AU - Battista, C.

AU - Maffezzoni, F.

AU - Chiloiro, S.

AU - Ferrante, E.

AU - Prencipe, N.

AU - Grasso, L.

AU - Gatto, F.

AU - Olivetti, R.

AU - Arosio, M.

AU - Barale, M.

AU - Bianchi, A.

AU - Cellini, M.

AU - Chiodini, I.

AU - De Marinis, L.

AU - Del Sindaco, G.

AU - Di Somma, C.

AU - Ferlin, A.

AU - Ghigo, E.

AU - Giampietro, A.

AU - Grottoli, S.

AU - Lavezzi, E.

AU - Mantovani, G.

AU - Morenghi, E.

AU - Pivonello, R.

AU - Porcelli, T.

AU - Procopio, M.

AU - Pugliese, F.

AU - Scillitani, A.

AU - Lania, A.G.

PY - 2020

Y1 - 2020

N2 - BACKGROUND: Vertebral fractures (VFs) are a frequent complication of acromegaly, but no studies have been so far published on effectiveness of antiosteoporotic drugs in this clinical setting. OBJECTIVE: To evaluate whether in real-life clinical practice bone active drugs may reduce the risk of VFs in patients with active or controlled acromegaly. STUDY DESIGN: Retrospective, longitudinal study including 9 tertiary care endocrine units. PATIENTS AND METHODS: Two hundred and forty-eight patients with acromegaly (104 males; mean age 56.00 ± 13.60 years) were evaluated for prevalent and incident VFs by quantitative morphometric approach. Bone active agents were used in 52 patients (20.97%) and the median period of follow-up was 48 months (range 12-132). RESULTS: During the follow-up, 65 patients (26.21%) developed incident VFs in relationship with pre-existing VFs (odds ratio [OR] 3.75; P

AB - BACKGROUND: Vertebral fractures (VFs) are a frequent complication of acromegaly, but no studies have been so far published on effectiveness of antiosteoporotic drugs in this clinical setting. OBJECTIVE: To evaluate whether in real-life clinical practice bone active drugs may reduce the risk of VFs in patients with active or controlled acromegaly. STUDY DESIGN: Retrospective, longitudinal study including 9 tertiary care endocrine units. PATIENTS AND METHODS: Two hundred and forty-eight patients with acromegaly (104 males; mean age 56.00 ± 13.60 years) were evaluated for prevalent and incident VFs by quantitative morphometric approach. Bone active agents were used in 52 patients (20.97%) and the median period of follow-up was 48 months (range 12-132). RESULTS: During the follow-up, 65 patients (26.21%) developed incident VFs in relationship with pre-existing VFs (odds ratio [OR] 3.75; P

KW - NEUROSCIENZE

KW - STUDIO CLINICO

KW - RIS

U2 - 10.1210/clinem/dgaa363

DO - 10.1210/clinem/dgaa363

M3 - Article

VL - 105

JO - J. Clin. Endocrinol. Metab.

JF - J. Clin. Endocrinol. Metab.

SN - 1945-7197

IS - 9

ER -